title: CA54/61 as a marker for epithelial ovarian cancer.
abstract: Using a new one-step, double-determinant enzyme immunoassay, we performed quantitative measurements of a mucin-type glycoprotein antigen (CA54/61) that we recently detected in sera of ovarian carcinoma patients. When the cutoff value was set at 12 units/ml, at which a high diagnostic efficiency was demonstrated [or at 20 units/ml (mean + 3 SD of healthy females)], the positive rates of ovarian serous, mucinous, clear cell, and endometrioid carcinomas were 76% (or 63%), 63% (or 55%), 57% (or 52%), and 50% (or 38%), respectively. Even in mucinous cystadenocarcinoma, more than one-half of the cases were positive, indicating the potential utility of the assay in the diagnosis of mucinous tumors. In sera from patients with benign ovarian tumors, only 9% (or 4%) of the cases were positive, indicating the quite high specificity of this test for ovarian carcinomas. To make a comparison between CA54/61 and CA125, we set the cutoff level of CA125 at 110 units/ml, at which value a high diagnostic efficiency was demonstrated [or at 35 units/ml (mean + 3 SD of healthy females)]. When both CA54/61 and CA125 were assessed in sera from 36 patients with mucinous cystadenocarcinoma, the positive rates of CA54/61 and CA125 were 64% (or 56%) and 36% (or 56%), respectively, suggesting that CA54/61 is of clinical value as a new tumor marker for ovarian cancers, including mucinous tumors.
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Nozawa
authors.forename: D
authors.initials: D
authors.lastname: Aoki
authors.forename: M
authors.initials: M
authors.lastname: Yajima
authors.forename: K
authors.initials: K
authors.lastname: Tsukazaki
authors.forename: T
authors.initials: T
authors.lastname: Kobayashi
authors.forename: E
authors.initials: E
authors.lastname: Kimura
authors.forename: Y
authors.initials: Y
authors.lastname: Terashima
authors.forename: N
authors.initials: N
authors.lastname: Inaba
authors.forename: H
authors.initials: H
authors.lastname: Takamizawa
authors.forename: Y
authors.initials: Y
authors.lastname: Negishi
mesh_terms: D000328:Adult; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D003536:Cystadenocarcinoma / Q000276:immunology*; D005260:Female; D006023:Glycoproteins / Q000032:analysis; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology*; D011247:Pregnancy; D012680:Sensitivity and Specificity
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; C072901:CA54-61 protein, human; D002272:Carcinoembryonic Antigen; D006023:Glycoproteins